# IceCure Reports First Quarter 2026 Financial Results: ProSense® Sales Increase Substantially in the U.S. and North America
Canonical URL: https://biopharmsignal.com/news/ICCM/icecure-reports-first-quarter-2026-financial-results-prosenser-sales-increase-substantially-in-the-u-s-and-north-america
Ticker: ICCM
Company: IceCure Medical
Source: IceCure Medical
Published: 2026-05-12 12:30 EST
Original Source URL: https://ir.icecure-medical.com
## Article Body
No article body is available yet.
## Recent Company News
- 2026-07-14 12:32 EST — [IceCure Expands U.S. Commercial Team to Meet Surging Demand for ProSense® Cryoablation](https://biopharmsignal.com/news/ICCM/icecure-expands-u-s-commercial-team-to-meet-surging-demand-for-prosense-cryoabla-7980c317) — Source: IceCure Medical
- 2026-07-06 12:11 EST — [IceCure Highlights Expanding Commercial Adoption of ProSense™ Cryoablation in Brazil Following FDA Clearance for Breast Cancer](https://biopharmsignal.com/news/ICCM/icecure-highlights-expanding-commercial-adoption-of-prosense-cryoablation-in-bra-814ddba1) — Source: IceCure Medical
- 2026-06-25 12:12 EST — [IceCure Regains Compliance with Nasdaq Minimum Bid Price Requirement](https://biopharmsignal.com/news/ICCM/icecure-regains-compliance-with-nasdaq-minimum-bid-price-requirement-7340e049) — Source: IceCure Medical
- 2026-06-23 12:10 EST — [IceCure Highlights New Peer-Reviewed Journal Article in Leading Surgery Journal, Demonstrating Cryoablation's Advantages Over Radiofrequency Ablation for Early-Stage Breast Cancer](https://biopharmsignal.com/news/ICCM/icecure-highlights-new-peer-reviewed-journal-article-in-leading-surgery-journal--2af39cdd) — Source: IceCure Medical
- 2026-06-17 17:14 EST — [IceCure Announces Pricing of $5.5 Million Private Placement Priced At a Premium to the Market Price with a Single Healthcare Focused Institutional Investor](https://biopharmsignal.com/news/ICCM/icecure-announces-pricing-of-5-5-million-private-placement-priced-at-a-premium-t-b922b2c5) — Source: IceCure Medical
## Related News
- 2026-07-22 20:15 EST — BFRG — [BullFrog AI to Participate in the BTIG Virtual Biotechnology Conference](https://biopharmsignal.com/news/BFRG/bullfrog-ai-to-participate-in-the-btig-virtual-biotechnology-conference-5880a10e)
- 2026-07-22 20:05 EST — AZTA — [Azenta Announces Fiscal 2026 Third Quarter Conference Call and Webcast](https://biopharmsignal.com/news/AZTA/azenta-announces-fiscal-2026-third-quarter-conference-call-and-webcast-48419fff)
- 2026-07-22 20:05 EST — VKTX — [Viking Therapeutics to Report Financial Results for Second Quarter 2026 on July 29, 2026](https://biopharmsignal.com/news/VKTX/viking-therapeutics-to-report-financial-results-for-second-quarter-2026-on-july--bbf2553f)
- 2026-07-22 20:01 EST — AXON — [Axon to Release Second Quarter 2026 Earnings on August 5, 2026](https://biopharmsignal.com/news/AXON/axon-to-release-second-quarter-2026-earnings-on-august-5-2026-66120902)
- 2026-07-22 12:39 EST — ARTL — [New Analysis of Over 50 Studies Showed that All the Non-Prescription CBD Products Researched Fell Short of Therapeutic Efficacy — Reinforcing the Case for Artelo's Optimized ART12.11 CBD Composition](https://biopharmsignal.com/news/ARTL/new-analysis-of-over-50-studies-showed-that-all-the-non-prescription-cbd-product-a3445432)